Brought to you by 
Mesoblast partners stem cell drugs exclusively with Cephalon
14 Jun 2016
Executive Summary
Australian regenerative medicine firm Mesoblast Ltd. has licensed Cephalon Inc. exclusive global rights to therapeutics derived from adult mesenchymal precursor stem cells (MPCs) for degenerative neurological and cardiovascular diseases including congestive heart failure, acute myocardial infarction, angina, peripheral vascular disease/critical limb ischemia, Parkinson's, stroke, multiple sclerosis, Huntington's, and Alzheimer's. The deal will also include cell products that expand hematopoietic stem cell (bone marrow) transplants for blood cancer patients.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mesoblast partners stem cell drugs exclusively with Cephalon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice